Company Overview
Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Therapeutics Issues Letter to Shareholders
Dec 22 2021, 7:30 AM EST

Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
Dec 17 2021, 9:00 AM EST

Abeona Therapeutics Announces Public Offering of Common Stock and Warrants
Dec 16 2021, 4:01 PM EST

Stock Overview
Symbol ABEO
Exchange Nasdaq
Market Cap 35.88m
Last Price $0.2447
52-Week $0.2058 - $3.09

02/14/2022 04:00 PM EST

Investor Relations
ir@abeonatherapeutics.com

Management Team
Vishwas Seshadri, Ph.D., M.B.A.
Chief Executive Officer, Director

Edward Carr
Chief Financial Officer, Principal Financial Officer

Greg Gin
Vice President, Investor Relations and Corporate Communications

Alison Hardgrove
Vice President, Human Resources

Brian Kevany, Ph.D.
Vice President, Chief Technical Officer

Scott Nogi
Vice President, Business Operations

Brendan O’Malley, J.D., Ph.D.
Senior Vice President, General Counsel

Abeona Therapeutics Inc.
1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company’s SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.